evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

48 questions · 48 findings · 3 reviews · Stroke

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 7 · 14.6%GRADE not reported 0 · 0%Very low 7 · 14.6%Low 17 · 35.4%Moderate 11 · 22.9%High 6 · 12.5%

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

NOAC (rivaroxaban) vs vitamin K antagonist (VKA)

Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

NOAC (rivaroxaban) showed no clear difference in clinically relevant non‐major bleeding compared with standard‐dose VKA (moderate certainty).

1 finding from 1 review

Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)

Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).

1 finding from 1 review

Anticoagulant drugs: VKA high dose vs vitamin K antagonist (VKA)

Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events

High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).

1 finding from 1 review